Your support is vital to our work.
Since Action Duchenne was founded in 2001, average life expectancy for people living with Duchenne in the UK, has increased by about a decade. Translarna, the first drug to treat the underlying cause of Duchenne is being received by the 10-15% of people that could benefit from it.
But our work is far from done.
We would like to keep you up to date with our life-changing activities, research updates, campaign objectives and all the work we do to improve the lives and find a cure for all living with Duchenne muscular dystrophy.
We will only contact you via the methods you choose and about the subjects/topics you decide; you give your consent to be contacted by:
You consent to receiving communication about the following topics:
Action Duchenne requires your email address to keep a record of your consent preferences. If you have chosen to opt out of receiving emails, we will only use your email address to record your preference accurately, and not to email you.